Temasek Invests in Gene Editing Food Company Pairwise
Posted on 02/04/2021
Gene editing food companies are gaining the attention of institutional investors. Durham, North Carolina-based Pairwise raised US$ 90 million in a Series B funding round. Funding for the round was led by Pontifax Global Food and Agriculture Technology Fund (Pontifax AgTech), and existing investor Deerfield Management Company. Singapore’s Temasek Holdings also invested in the Series B round as a new investor. Existing investor Leaps by Bayer also participated in the round as well.
Pairwise uses CRISPR technology to create new fruits and vegetables. Wilson Sonsini Goodrich & Rosati advised Temasek Holdings in the transaction.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Pairwise Raises $90 Million to Bring New Varieties of Fruits and Vegetables to Market
February 3, 2021 GMT
DURHAM, N.C. (BUSINESS WIRE) Feb 3, 2021
Pairwise announced the closing of its $90 million Series B funding round, signaling a new frontier in healthy, sustainable food innovation. Funding for the round was led by Pontifax Global Food and Agriculture Technology Fund (Pontifax AgTech), a pioneering growth capital investor in food and agriculture technology, and existing investor Deerfield Management Company (Deerfield), an investment firm dedicated to advancing healthcare through investment, information and philanthropy. Also joining the Series B round are new investor Temasek, an investment company headquartered in Singapore, and existing investor Leaps by Bayer, which invests in paradigm-shifting advances in the life sciences sector, including agriculture and health.
To embed, copy and paste the code into your website or blog:
The question of what constitutes insider trading has been litigated for decades. Many thought that a series of Supreme Court cases such as
Dirks v. SEC, 462 U.S. 646 (1983) and its progeny had largely resolved the question about the basic elements of the unlawful conduct.
Blaszczak v. U.S., 947 F. 3rd 19 (2nd Cir. 2019) however, an action prosecuted under the federal wire fraud statute and an fraud statute created as part of the Sarbanes-Oxley Act (“SOX”), suggested that perhaps proof of elements like the “personal benefits” test can be bypassed – a shortcut to insider trading lability.
COVID Test Results in 15min with New At-Home Test Service from Ready
COVID Test Results in 15min with New At-Home Test Service from Ready
Ready, an on-demand healthcare service, today announces in-home rapid COVID-19 testing with results in 15 minutes or less. The rapid test can be run from start to finish in the home, increasing the access to widespread testing outside of healthcare facilities. This testing capability not only reduces potential exposure at hospitals or testing sites, but also provides patients with fast and convenient results.
Why Readys COVID Test is Different Ready sends a healthcare professional with the appropriate personal protective equipment directly to a patients home or office – no lines, no increased risk of exposure “ just fast, private testing.
17.01.2021
Valneva: Valneva, an Austrian/French specialty vaccine company focused on prevention against diseases with major unmet needs, today announced an amendment to the terms of its existing debt facility with US-based healthcare investment firms Deerfield Management Company and OrbiMed. Noting the COVID-19 pandemic impact on the travel industry, and following a temporary waiver of the revenue covenant for the second half of 2020, Valneva, Deerfield and OrbiMed have agreed to modify this covenant for 2021 and 2022, replacing the twelve month rolling Euro 115 mn with quarterly minimum revenues representing an annual total of Euro 64 mn in 2021 and an annual total of Euro 103.75 mn in 2022. The parties have also agreed to modify the minimum cash requirement to Euro 50 mn for 2021 and 2023 and to Euro 35 mn for the following years.